drugset / Trial / NCT03312205
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Phase 1/2
Unknown
50 enrolled
Hebei Senlang Biotechnology Inc., Ltd.
Beijing Lu Daopei Hospital · collabHebei Yanda Ludaopei Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and lymphoid malignancies. A total of 50 patients are planned to be enrolled over a period of 2 years.
Timeline
- Start
- 2017-08-29
- Primary completion
- 2019-08-29
- Completion
- 2023-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cells | Cell therapy | — | — |